Published in MedGenMed on November 14, 2006
Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. Immunology (2013) 0.85
Safety Profile of Anticancer and Immune-Modulating Biotech Drugs Used in a Real World Setting in Campania Region (Italy): BIO-Cam Observational Study. Front Pharmacol (2017) 0.75
Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 83.56
Dendritic cells and the control of immunity. Nature (1998) 56.54
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science (1987) 49.88
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med (2001) 44.67
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
Selective in vitro growth of T lymphocytes from normal human bone marrows. Science (1976) 15.73
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (1993) 15.70
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol (2003) 15.10
Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 9.51
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med (1982) 8.74
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol (2003) 8.17
EGFR and cancer prognosis. Eur J Cancer (2001) 7.52
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 6.36
Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med (2000) 5.62
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res (2004) 5.23
Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature (1990) 5.15
Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. J Clin Oncol (2004) 5.08
Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol (2001) 4.97
Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med (1992) 4.76
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood (2001) 4.76
Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell (2005) 4.73
Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol (2005) 3.39
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 3.25
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 3.01
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. Oncologist (2003) 2.53
Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Res (1995) 2.50
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res (1981) 2.49
Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia (2001) 2.30
The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer (1993) 2.23
Cancer vaccines. Nat Med (1998) 2.22
Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am (1998) 2.14
Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol (1994) 2.10
The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol (1987) 2.04
Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (1). N Engl J Med (1992) 1.95
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst (1993) 1.91
An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med (1990) 1.89
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol (1999) 1.87
Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res (1987) 1.87
Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon. J Exp Med (1984) 1.81
Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol (1998) 1.77
Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Semin Oncol (2002) 1.76
Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer (1998) 1.69
Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood (1994) 1.64
Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. Blood (1987) 1.63
Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis. J Clin Oncol (1992) 1.62
A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A (2001) 1.49
Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther (1997) 1.47
Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun (1999) 1.46
DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon-gamma. Eur J Immunol (1987) 1.34
The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer (2001) 1.33
CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge. J Immunol (1998) 1.32
Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology (1996) 1.26
Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control (2002) 1.25
Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. Cancer Res (1998) 1.24
Human immune response to monoclonal antibodies. J Immunother Emphasis Tumor Immunol (1994) 1.22
Angiogenesis: role of calcium-mediated signal transduction. Proc Natl Acad Sci U S A (1995) 1.21
An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. Cancer J Sci Am (1997) 1.20
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood (2001) 1.17
CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol (1998) 1.15
Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood (1998) 1.14
Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol (1998) 1.13
Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses. Cancer (1987) 1.12
Successful treatment of an angiogenic disease. N Engl J Med (1989) 1.12
Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol (2000) 1.11
Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother (2004) 1.11
Epitope specificity of the anti-(B cell lymphoma) monoclonal antibody, LL2. Cancer Immunol Immunother (1993) 1.10
Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol (1995) 1.10
A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol (1989) 1.04
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. Hematol J (2004) 1.03
Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer (1996) 1.03
Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg (1998) 1.00
Beta dose point kernels for radionuclides of potential use in radioimmunotherapy. J Nucl Med (1989) 0.99
Comparison of intramuscular and intravenous recombinant alpha-2 interferon in melanoma and other cancers. Ann Intern Med (1985) 0.98
Low-dose, fractionated radioimmunotherapy for B-cell malignancies using 131I-Lym-1 antibody. Cancer Biother Radiopharm (1998) 0.96
CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol (1999) 0.95
Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. Semin Oncol (1993) 0.95
TNP-470 (AGM-1470): mechanisms of action and early clinical development. Eur J Cancer (1996) 0.94
Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am J Pathol (2002) 0.91
Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol (1995) 0.91
Radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol (1999) 0.88
Regulation of human natural killer cell activity by interferon-gamma: lack of a role in interleukin 2-mediated augmentation. J Immunol (1986) 0.88
Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer Lett (2005) 0.87
Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer (1996) 0.87
Therapeutic vaccination for cancer. Clin Immunol (2000) 0.87
Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer (1993) 0.87
Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia. Cancer (1994) 0.86
An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice. Vaccine (2001) 0.85
Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol (1998) 0.83
Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma. Clin Cancer Res (1999) 0.83
Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN alpha, r-IFN gamma, and r-IFN alpha + cimetidine) in disseminated malignant melanoma. J Cancer Res Clin Oncol (1987) 0.82
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects. J Clin Oncol (1993) 0.82
Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects. Cancer Immunol Immunother (1987) 0.82
Neuroprotective role of melatonin in oxidative stress vulnerable brain. Indian J Physiol Pharmacol (2003) 1.04
Sequence and expression analysis of the thioredoxin protein gene family in rice. Mol Genet Genomics (2008) 0.97
Current drug therapy of protozoal diarrhoea. Indian J Pediatr (2004) 0.94
Pro-oxidant and anti-oxidant status in patients of sickle cell anaemia. Indian J Clin Biochem (2004) 0.91
Pharmacoeconomics. Natl Med J India (2004) 0.91
Add-on melatonin improves sleep behavior in children with epilepsy: randomized, double-blind, placebo-controlled trial. J Child Neurol (2005) 0.89
Post traumatic epilepsy: a review of scientific evidence. Indian J Physiol Pharmacol (2006) 0.89
Outcomes of patients with unresected stage III and stage IV non-small cell lung cancer: A single institution experience. Lung India (2013) 0.87
Effects of add-on melatonin administration on antioxidant enzymes in children with epilepsy taking carbamazepine monotherapy: a randomized, double-blind, placebo-controlled trial. Epilepsia (2004) 0.86
Add-on melatonin improves quality of life in epileptic children on valproate monotherapy: a randomized, double-blind, placebo-controlled trial. Epilepsy Behav (2004) 0.82
Osteoarthritic femoral articular cartilage of knee joint in man. Nepal Med Coll J (2006) 0.79
Immunohistochemical analysis of ageing and osteoarthritic articular cartilage. J Mol Histol (2010) 0.79
A randomized, double-blind, placebo controlled trial of melatonin add-on therapy in epileptic children on valproate monotherapy: effect on glutathione peroxidase and glutathione reductase enzymes. Br J Clin Pharmacol (2004) 0.79
Corpus callosum morphometry: comparison of fresh brain, preserved brain and magnetic resonance imaging values. Anat Sci Int (2008) 0.78
Modulation of serum concentrations of melatonin by carbamazepine and valproate. Indian J Physiol Pharmacol (2006) 0.76
Treatment of hypertensive retinopathy. Surv Ophthalmol (2002) 0.75
Computerized morphometric analysis of human femoral articular cartilage. ISRN Rheumatol (2012) 0.75
Mother's use of medication in their children of preschool age. Indian J Public Health (2005) 0.75
Status of blood antioxidant enzymes in alcoholic cirrhosis. Indian J Physiol Pharmacol (2003) 0.75
Disposition of muscularis propria and nerve elements in the lip of the ileocaecal valve. Nepal Med Coll J (2005) 0.75
Morphometry of myenteric neurons in stomach. Nepal Med Coll J (2007) 0.75
Radiation therapy outcomes in muscle invasive urinary bladder cancer: A single institution experience. Indian J Cancer (2016) 0.75
Can large animal experiments be totally replaced by alternatives? Indian J Physiol Pharmacol (2009) 0.75
Bilateral variant origin of pectoralis major. Nepal Med Coll J (2006) 0.75
Clustered-dot halftoning with direct binary search. IEEE Trans Image Process (2012) 0.75